457-97-6 Usage
General Description
3-[(4-Fluorobenzyl)oxy]benzoic acid is a chemical compound with the molecular formula C14H11FO3. It is a white solid that is used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical intermediates. 3-[(4-FLUOROBENZYL)OXY]BENZOIC ACID contains a benzoic acid moiety with an ether linkage to a 4-fluorobenzyl group. It is used as a precursor for the synthesis of various pharmacologically active compounds, and its structure allows for modification to create new pharmaceuticals with improved efficacy and reduced side effects. This chemical has potential applications in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 457-97-6 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,5 and 7 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 457-97:
(5*4)+(4*5)+(3*7)+(2*9)+(1*7)=86
86 % 10 = 6
So 457-97-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H11FO3/c15-12-6-4-10(5-7-12)9-18-13-3-1-2-11(8-13)14(16)17/h1-8H,9H2,(H,16,17)
457-97-6Relevant articles and documents
Hydrophobicity-oriented drug design (HODD) of new human 4-hydroxyphenylpyruvate dioxygenase inhibitors
Ndikuryayo, Ferdinand,Kang, Wei-Ming,Wu, Feng-Xu,Yang, Wen-Chao,Yang, Guang-Fu
, p. 22 - 31 (2019/01/26)
Involved in the tyrosine degradation pathway, 4-hydroxyphenylpyruvate dioxygenase (HPPD) is an important target for treating type I tyrosinemia. To discover novel HPPD inhibitors, we proposed a hydrophobicity-oriented drug design (HODD) strategy based on the interactions between HPPD and the commercial drug NTBC. Most of the new compounds showed improved activity, compound d23 being the most active candidate (IC50 = 0.047 μM) with about 2-fold more potent than NTBC (IC50 = 0.085 μM). Therefore, compound d23 is a potential drug candidate to treat type I tyrosinemia.
